HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Flow cytometric DNA analysis of vascular soft tissue tumors, including African endemic-type Kaposi's sarcoma.

Abstract
Vascular tumors of the soft tissue display a wide spectrum of histologic features and biologic behavior. Flow cytometric DNA analysis was performed on 40 vascular tumors, including nine African endemic-type Kaposi's sarcomas, nine angiosarcomas, seven hemangiopericytomas, six glomus tumors, and nine capillary hemangiomas. Six of the nine angiosarcoma cases (67%) and one of the seven hemangiopericytomas cases (14%) were aneuploid. All benign vascular tumors and Kaposi's sarcomas were diploid. Clinically, five of the six angiosarcoma patients with aneuploidy died within 2 to 28 months, while the remaining patient, who had the smallest tumor (2 x 1 cm), survived more than 4 years after the initial diagnosis was made. All three angiosarcoma patients with diploidy died within 10 to 14 months. One hemangiopericytoma patient with aneuploidy died within 1 month. No cases of benign tumor recurred. These results suggest that most vascular tumors, which generally follow a benign clinical course, were diploid and that the majority of those with a poor outcome were aneuploid. However, flow cytometrically assessed DNA ploidy has no prognostic value in angiosarcomas or hemangiopericytomas.
AuthorsH Eto, K Toriyama, N Tsuda, Y Tagawa, H Itakura
JournalHuman pathology (Hum Pathol) Vol. 23 Issue 9 Pg. 1055-60 (Sep 1992) ISSN: 0046-8177 [Print] United States
PMID1516928 (Publication Type: Journal Article)
Chemical References
  • DNA, Neoplasm
Topics
  • Adolescent
  • Adult
  • Blood Vessels (pathology)
  • Child
  • Child, Preschool
  • DNA, Neoplasm (analysis)
  • Flow Cytometry
  • Hemangiopericytoma (blood supply, genetics)
  • Hemangiosarcoma (blood supply, genetics)
  • Humans
  • Infant
  • Middle Aged
  • Sarcoma, Kaposi (blood supply, classification, genetics)
  • Soft Tissue Neoplasms (blood supply, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: